Psoriasis: guidance on assessment and referral.

This concise guideline summarises the key recommendations from the recent National Institute for Health and Care Excellence (NICE) clinical guideline on the assessment and management of psoriasis (CG153) that are relevant to the non-dermatologist. The aim is to highlight important considerations for assessment and referral of people with psoriasis, including identification of relevant comorbid conditions. Psoriasis is a common inflammatory skin condition and, especially when severe, can be associated with increased risk of cardiovascular disease, diabetes and depression. Functional, psychological and social morbidity can also be encountered, and the extent of the disability is frequently underestimated. Importantly, highly effective treatments are available. Appropriate assessment and referral of people with psoriasis therefore has the potential to improve outcomes by correctly identifying the appropriate treatment pathway. Assessment should involve not only disease severity but also the impact on patient well-being and whether the patient has any comorbid conditions, such as psoriatic arthritis, which requires rapid referral to a rheumatologist.

[1]  O. Moghraby,et al.  Depression in children and young people: identification and management in primary, community and secondary care (NICE guideline CG28) , 2015, Archives of Disease in Childhood: Education & Practice Edition.

[2]  J. Barker,et al.  Psoriasis and cardiovascular disease: where is the risk? , 2013, The Journal of investigative dermatology.

[3]  Ole Ahlehoff Psoriasis and Cardiovascular Disease: epidemiological studies. , 2011, Danish medical bulletin.

[4]  D. Gladman,et al.  Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? , 2011, Annals of the rheumatic diseases.

[5]  H. Tey,et al.  Targeted treatment of pruritus: a look into the future , 2011, The British journal of dermatology.

[6]  Andrea B Troxel,et al.  The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. , 2010, Archives of dermatology.

[7]  G. Vena,et al.  Psoriasis and cardiovascular disease , 2010, Dermatologic therapy.

[8]  P. Helliwell,et al.  The prevalence of psoriatic arthritis in people with psoriasis. , 2009, Arthritis and rheumatism.

[9]  P. Helliwell,et al.  Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. , 2009, Clinical and experimental rheumatology.

[10]  S. Piaserico,et al.  Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.

[11]  Tamara Brown,et al.  Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children.NICE Clinical Guideline 43 , 2006 .

[12]  S. Chimenti,et al.  European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey , 2006, The British journal of dermatology.

[13]  R. Stern,et al.  Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. , 1998, Archives of dermatology.

[14]  D. Ashcroft,et al.  Systematic review of the incidence and prevalence of psoriasis , 2011 .

[15]  Nice Smoking cessation services , 2008 .

[16]  J. Karvonen,et al.  Excess mortality related to alcohol and smoking among hospital-treated psoriatic patients , 1999 .